Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer
15 October 2019 - 11:30PM
Business Wire
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Andrew
Dickinson has been appointed Chief Financial Officer (CFO),
effective November 1. Mr. Dickinson currently serves as the
company’s Executive Vice President, Corporate Development and
Strategy, and in his new role he will continue to be a member of
the senior leadership team, reporting to Daniel O’Day, Chairman and
Chief Executive Officer.
Mr. Dickinson joined Gilead in 2016 and has transformed the way
that the company approaches corporate development, expanding the
kinds of transactions executed and implementing a broader and more
strategic approach to deal-making. He served as the architect of
the company’s 2017 acquisition of Kite Pharma, Inc. and of the
10-year, global research collaboration with Galapagos NV announced
earlier this year. In his new role, Mr. Dickinson will retain
responsibility for the corporate development and strategy
organization.
“Andy is an exceptional, highly strategic leader. In addition to
his impressive business and financial acumen and broad experience,
Andy possesses strong creativity and vision. This has been evident
in the way Gilead has approached acquisitions and partnerships
under Andy’s leadership,” commented Mr. O’Day. “Over the past
months, one of my key priorities has been to ensure we have an
outstanding team of leaders to shape Gilead’s long-term success. I
am pleased that with Andy’s appointment as CFO, we now have our
full leadership team in place.”
Prior to his tenure at Gilead, Mr. Dickinson worked for nine
years at Lazard Frères & Co., where he was Global Co-Head of
Healthcare Investment Banking. Prior to Lazard, he was General
Counsel and Vice President of Corporate Development at Myogen,
Inc., which was acquired by Gilead in 2006. Earlier in his career,
he worked as a lawyer specializing in mergers and acquisitions. Mr.
Dickinson received his B.A. in molecular, cellular and
developmental biology at University of Colorado at Boulder and
holds a J.D. from Loyola University of Chicago.
“It has been an incredible privilege to work at Gilead for the
past three years and I am honored to have the opportunity to serve
as the company’s next CFO,” said Mr. Dickinson. “I am looking
forward to working with the talented teams across Gilead in this
new role as we together seek to improve care for millions of people
around the world who are in need of better treatment options.”
Mr. Dickinson will work closely with Robin Washington, who
currently serves as Executive Vice President and Chief Financial
Officer, to ensure a smooth transition. As previously announced,
Ms. Washington will remain at Gilead in an advisory capacity
through the completion of the company’s reporting of 2019 financial
results early next year.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191015005435/en/
Sung Lee, Investors (650) 524-7792
Marni Kottle, Media (650) 522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024